<DOC>
	<DOCNO>NCT01385566</DOCNO>
	<brief_summary>This study compare safety immunogenicity ZOSTAVAX™ ( V211 ) administer intradermally subcutaneously various dos .</brief_summary>
	<brief_title>A Study Intradermal Administration ZOSTAVAX™ ( V211-051 AM2 )</brief_title>
	<detailed_description>This exploratory , randomize , partially blind , multicenter clinical study design compare safety biomarkers varicella zoster virus immunogenicity administer ZOSTAVAX™ ( V211 ) various dos intradermally subcutaneously healthy male female participant 50 year age old .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Prior history varicella ( chickenpox ) residence country endemic varicella zoster virus infection least 30 year Temperature less 100.4 °F day vaccination Female participant reproductive potential must negative pregnancy test agree remain abstinent use two acceptable contraceptive method 3 month postvaccination In good health History hypersensitivity reaction vaccine component , include gelatin neomycin Household exposure pregnant woman chickenpox vaccinated varicella immunosuppressed/immunodeficient individual Household workplace exposure child 18 month younger vaccinate varicella Prior history herpes zoster Prior receipt varicella zoster vaccine Received expect receive immune globulin and/or blood product 5 month prior randomization 42 day vaccination On immunosuppressive therapy Known suspect immune dysfunction Received live virus vaccine schedule receive live virus vaccine 4 week prior study vaccination completion study visit Received inactivate vaccine schedule receive inactivate vaccine 7 day prior study vaccination 7 day postvaccination , except inactivate influenza vaccine Not ambulatory Pregnant breastfeeding Use nontopical antiviral therapy activity herpes virus Active untreated tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>